Trial · NCT03370653
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of patients with modified clinical signs | 26 weeks | Changes in physical examination and vital signs |
| Primary | Number of patients with modified biological values | 26 weeks | Change from baseline in laboratory safety tests (coagulation, liver enzymes and crystalluria) 12-lead-ECG and bone biomarkers. |
| Primary | Incidence of AEs/SAEs | 26 weeks | Incidence of AEs/SAEs, patient withdrawals from study due to AEs/SAEs, |
| Primary | 12-lead ECG | 26 weeks | Change from Baseline in ECG |
| Secondary | Mobility: 6-minute walk test | 26 weeks | Change from baseline in 6-minute walk test |
| Secondary | Mobility: 9-hole PEG test | 26 weeks | Change from baseline in 9-hole PEG test |
| Secondary | Mobility: range of motion of the shoulder | 26 weeks | Change from baseline in range of motion of the shoulder |
| Secondary | Pain assessment | 26 weeks | Change from Baseline in Brief Pain Inventory (BPI) |
| Secondary | Respiratory function | 26 weeks | Change from Baseline in FEV1 |
| Secondary | Respiratory function | 26 weeks | Change from Baseline in FVC |
| Secondary | Respiratory function | 26 weeks | Change from Baseline in MVV |
| Secondary | Cardiac and vascular function | 26 weeks | Change from Baseline in echocardiogram |
| Secondary | Cardiac and vascular function | 26 weeks | Change from Baseline in carotid intima media thickness Odiparcil concentration remaining in patient plasma 12 hours following the last intake of investigational product at visits V4 and V7. An identification of odiparcil metabolites in plasma at visit V2. |
| Secondary | Audiology assessments | 26 weeks | Change from Baseline in pure tone audiometry |
| Secondary | Audiology assessments | 26 weeks | Change from Baseline in whisper voice test |
| Secondary | Ophthalmology assessments | 26 weeks | Change from Baseline in corneal opacification |
| Secondary | Ophthalmology assessments | 26 weeks | Change from Baseline in level of retinopathy |
| Secondary | Ophthalmology assessments | 26 weeks | Change from Baseline in optic nerve involvement, |
| Secondary | Ophthalmology assessments | 26 weeks | Change from Baseline in intra-ocular pressure |
| Secondary | Ophthalmology assessments | 26 weeks | Change from Baseline in visual acuity |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03370653/registered